Insulin Aspart
Title: Insulin Aspart
CAS Registry Number: 116094-23-6
CAS Name: 28B-L-Aspartic acid-insulin (human)
Additional Names: AspB28-insulin (human); B28-asp-insulin
Manufacturers' Codes: INA-X14
Trademarks: Novorapid (Novo Nordisk)
Literature References: Rapid-acting insulin analog produced by recombinant DNA technology. Identical to human insulin except for one amino acid substitution. Prepn: J. Brange et al., Nature 333, 679 (1988). Pharmacology and safety: V. Dall, Arzneim.-Forsch. 49, 463 (1999). Clinical pharmacokinetics and dynamics: S. R. Mudaliar et al., Diabetes Care 22, 1501 (1999). Clinical trial for postprandial glycemic control in type 1 diabetics: P. Raskin et al., ibid. 23, 583 (2000). Review of pharmacology and clinical experience: K. L. Simpson, C. M. Spencer, Drugs 57, 759-765 (1999).
Therap-Cat: Antidiabetic.
Keywords: Antidiabetic; Hormones/Analogs.

Others monographs:
Quinovic AcidDeuterium OxidePhytochlorinLactobacillic Acid
DicumarolPiperidolateDecamethylene GlycolPotassium Perchlorate
LeucocyanidinPepstatinEthyl MalonateCadmium Chloride
FumagillinThozalinonep-Cresyl PhenylacetateHydrazine Hydrate
©2016 DrugLead US FDA&EMEA